High-Frequency Ultrasound of Multiple Arterial Areas Reveals Increased Intima Media Thickness, Vessel Wall Appearance, and Atherosclerotic Plaques in Systemic Lupus Erythematosus

Christina Svensson¹,²*, Per Eriksson³, Helene Zachrisson¹,²† and Christopher Sjöwall³†

¹ Department of Clinical Physiology, University Hospital, Linköping, Sweden, ² Department of Health, Medicine and Caring Sciences, Linköping University, Linköping, Sweden, ³ Division of Inflammation and Infection, Department of Biomedical and Clinical Sciences, Linköping University, Linköping, Sweden

Introduction: Despite improved therapies and management, patients with systemic lupus erythematosus (SLE) still have increased risks of cerebrovascular and cardiovascular disease. High-frequency ultrasound (US) provides an opportunity to distinguish atherosclerosis from inflammation in the vessels. We hypothesized that an extended US protocol may add information regarding vascular affection in SLE.

Methods: Sixty patients (52 women, 8 men; mean age 43.2 ± 11.3 years) with SLE characterized by either lupus nephritis (LN; n = 20), antiphospholipid syndrome (APS; n = 20), or skin and joint involvement (n = 20) as well as matched healthy controls (n = 60) were included. Intima-media thickness (IMT), assessment of vessel walls, and plaque occurrence were recorded using high-frequency US (GE Logic E9) in common carotid, internal carotid, brachiocephalic, subclavian, axillary, common femoral, and proximal superficial femoral arteries as well as in the aortic arch.

Results: For the entire SLE group, IMT was increased in the internal carotid artery (0.52 ± 0.17 vs. 0.45 ± 0.09 mm, p = 0.004), the common femoral artery (0.57 ± 0.23 vs. 0.49 ± 0.11 mm, p < 0.01), the subclavian artery (0.58 ± 0.19 vs. 0.53 ± 0.13 mm, p = 0.02), and the aortic arch (1.21 ± 0.63 vs. 0.98 ± 0.25 mm, p = 0.002) compared to controls. These differences were primarily observed in the APS and LN groups compared to controls. Vessels with increased IMT ≥0.9 mm had a smooth, medium echogenic appearance in areas free of atherosclerotic plaques. Atherosclerotic plaques were detected in 15/60 patients (25%) as compared to 2/60 of the controls (3%). Plaques were predominantly (67%) located in the carotid bifurcation. Multivariate analysis revealed influence of age on IMT in all vessel areas. Furthermore, in the common femoral artery, sagittal abdominal diameter, diastolic blood pressure, and cholesterol all showed association with increased IMT.
INTRODUCTION

Systemic lupus erythematosus (SLE) is an autoimmune inflammatory disease affecting multiple organ systems which often affects young females (1). Increased morbidity and mortality, particularly from cardiovascular disease (CVD), remains a reality in SLE (2, 3). The increased risk has been estimated to 2- to 10-fold compared to the general population, but as high as 50-fold among female SLE patients aged 35–44 years (4–6). In Sweden, the relative risk of ischemic stroke in SLE is more than doubled compared to the general population (7). According to Gustafsson et al., patients with lupus nephritis (LN) display carotid plaques twice as often as patients without renal involvement and matched controls (3).

Antiphospholipid syndrome antibodies (aPL) form a heterogeneous group of antibodies targeting phospholipid-binding proteins and phospholipids. The aPL included in the APS classification criteria are lupus anticoagulant, anticardiolipin [immunoglobulin G (IgG)/IgM], and anti–β2-glycoprotein I antibodies (IgG/IgM) (8). These antibodies have important roles, e.g., by interfering with the coagulation system. Up to 40% of all SLE cases display elevated levels of any aPL at some point during the course of the disease, yet only approximately half of these SLE cases will fulfill the APS classification criteria over time. Presence of aPL among patients with SLE is associated with acquired organ damage and a more severe course of disease (9, 10).

High-frequency ultrasound (US) provides an opportunity to distinguish atherosclerosis from inflammation in the vessel walls. Measurement of intima-media thickness (IMT) with high-frequency US in the common carotid artery constitutes a validated method to assess early atherosclerosis (11). Different appearance of the vessel walls is seen depending on the cause of vascular affection.

**Conclusion:** Among SLE patients without presence of plaques, an extended US protocol revealed increased wall thickness with predominantly medium echogenic appearance highlighting possibly inflammation or early atherosclerosis. The appearance of vessel walls has not previously been studied in detail. An increased number of plaques were found in SLE compared to age- and sex-matched healthy controls. We found similar risk factors for increased IMT and occurrence of plaques, possibly indicating atherosclerotic mechanisms rather than inflammation.

**Keywords:** systemic lupus erythematosus, ultrasound, IMT, plaque, vessel wall

**MATERIALS AND METHODS**

**Subjects**

In this cross-sectional study, we included 60 patients (52 women, 8 men; mean age 43.2 ± 11.3 years), diagnosed with SLE based on fulfillment of the 1982 American College of Rheumatology (ACR) and/or the 2012 Systemic Lupus Collaborating Clinics (SLICC) classification criteria as detailed in Supplementary Table 1 (20, 21). Patients above 63 years of age were excluded due to a higher background risk of atherosclerosis dependent on age (22), whereas patients below the age of 23 years were excluded due to an overall short duration of SLE. All patients were followed longitudinally within the frame of an observational research program KLURING (a Swedish acronym for Clinical Lupus Register In North-eastern Gotland) at the Rheumatology Unit, Linköping University hospital, as previously detailed (23). Acquired organ damage was assessed by the SLICC/ACR damage index (SDI) and disease activity by the SLE disease activity index 2000 (SLEDAI-2K) for each patient, which was recorded.
from their closest regular visit to rheumatologist (24, 25). Mean time between examination and disease activity assessment was 3.8 months; 29/60 (48%) patients had a serologically active, but clinically quiescent SLE (26), and 50/60 cases (83%) had Caucasian ancestry.

Sixty patients included in KLURING were selected and divided into 3 phenotypic subgroups with different SLE manifestations. The subgroups were matched between each other 1:1:1 according to sex and age; 20 cases meeting the renal disorder ACR criterion for LN (20) in the absence of APS, 20 cases meeting APS criteria (8) in the absence of LN, and 20 cases with skin and joint involvement in the absence of LN and APS.

Sixty healthy age- and sex-matched (1:1 to the 60 SLE cases), non-medicated controls without clinical signs of inflammatory or atherosclerotic disease (52 women and 8 men; mean age 42.9 ± 11.5 years), were examined using the same protocol as for the patients. The healthy controls were all of Caucasian ethnicity and had all been recruited from the hospital staff.

**Background Variables**

We obtained demographic data from all subjects regarding height, weight, waist circumference and sagittal abdominal diameter. Variables concerning age, sex, smoking habits and ongoing pharmacotherapy were collected. Blood pressure was determined with oscillometric technique (Dinamap PRO 200 Monitor, Critikon, Tampa, FL, USA).

**Laboratory Measurements**

Standard cardiovascular and inflammatory laboratory test with measurements of total cholesterol, triglycerides, high-density lipoprotein (HDL), low-density lipoprotein (LDL), plasma creatinine and C-reactive protein with high sensitive technique (hsCRP) were collected after 12-h overnight fasting. Presence of serological disease activity, with anti–double-stranded DNA antibodies using addressable laser bead immunoassay (FIDIS™ Connective profile, Solonium software version 1.7.1.0, Theradiag, Croissy-Beaubourg, France) and plasma analyses complement protein 3 (C3) and 4 (C4), was controlled for at the closest regular visit to rheumatologist (27).

**US**

For the US measurements, a GE Logic E9 US system (LOGIQ E9 XDclear 2.0 General Electric Medical Systems US, Wauwatosa, WI, USA) with linear transducer L2-9 MHz was used. For the aortic arch, a C1-6 MHz transducer was used. IMT was measured in common carotid artery (CCA), internal carotid artery (ICA), subclavian artery (SCA), axillary artery (AxA), common femoral artery (CFA), superficial femoral artery (SFA) and the aortic arch. Measuring principles are shown in Figure 1a. Both sides were investigated. The procedure has been described previously (28), with an addition of CFA and SFA in this study. For IMT measurements in CCA a 10 mm wide box was placed over the common carotid artery far wall, near (10 mm) the carotid bifurcation. A mean value of all measured far wall points in the box was presented. For validation of the method two repeated measurements were performed. Maximum systolic flow velocity was measured in all vessels to evaluate possible arterial stenosis.

Plaques were defined as focal areas in the vessel wall where IMT showed increase of either 0.5 mm or 50% compared to the IMT in the adjacent wall.

In areas free of plaques with IMT ≥0.9 mm for carotid and central arteries, and ≥1.2 mm for the aortic arch, the vessel wall was assessed regarding echogenicity (low–medium–high). Furthermore, distribution and presence of fibrotic stripes were noted. The cutoff value of ≥0.9 mm was chosen due to the latest European Society of Hypertension/European Society of Cardiology (ESH/ESC) hypertension guidelines (29). For the aortic arch a higher cutoff value was chosen due to generally higher aortic arch IMT values among our healthy controls, according to results from earlier studies (30). Plaques were assessed regarding echogenicity (low–medium–high), distribution, irregularity (homogeneity or heterogeneity) and cap (smooth surface or ulceration).

A standardized examination procedure was used in all individuals. The participant had to rest 15 min before the test which was performed in a room with a temperature of 25°C, dim lighting and no outer disturbances. All participants were asked to refrain from coffee 4 h prior to the measurements.

The same vascular sonographer performed all US examinations and offline measurements performed after the exam. The sonographer was blinded to which classification criteria the patients with SLE fulfilled, but not blinded to whether the participants were patients or controls.

**Ethics Considerations**

Oral and written informed consent was obtained from all patients and healthy controls. The study protocol was performed according to the Declaration of Helsinki and approved by the
Regional Ethics Board in Linköping (ref. M75-08, 2013/33-31 and ref. 2017/572-32).

**Statistical Methods**

According to the central limit theorem, sufficiently many subjects were included to allow use of methods that rely on the normal distribution. Demographic values and IMT are presented as mean ± SD. Differences between the whole SLE group and controls were calculated using Student’s t-test. Differences between subgroups were calculated using one-way ANOVA. For binary variables chi square test was used. Univariate linear regression was used to establish relationship between IMT values and each of the variables in Table 1. Multivariate linear regression and logistic regression were used to examine factors explaining IMT and presence of plaques. All variables significant in the univariate model were combined and a stepwise procedure until a multiple model with only significant variables remained was performed. For missing data, no imputation analysis was performed. Statistical analyses were performed using SPSS version 25.0 (IBM, Armonk, NY USA).

**RESULTS**

Basic demographics, laboratory data and ongoing medical therapies are shown in Table 1.

**Intima-Media Thickness**

As shown in Table 2, the average IMT (right and left side) of the entire SLE group was increased compared to controls in ICA, CFA, SCA as well as in the aortic arch whereas no significant differences were detected in CCA, SFA and AxA.

In relation to SLE phenotypes, IMT was still increased in the APS group compared to controls in CFA ($p = 0.006$), in the aortic arch ($p < 0.001$) and in ICA ($p = 0.01$). In the LN group, IMT in ICA was increased compared to controls ($p = 0.002$). No significant differences were observed between SLE phenotypes in other vessels.

The reproducibility between two repeated measurements of IMT in the whole group of patients showed a difference of mean $0.06 ± 0.19$ mm in right and left CCA (not significant). In the healthy controls this value was $0.08 ± 0.06$ (not significant).

**Vessel Wall Assessment**

Increased IMT $≥0.9$ mm observed in SLE patients showed a medium echogenic, homogenous wall thickening that can be seen in inflammatory vascular disease (Figure 1b). This appearance differs from vessel wall changes that can be seen in later stages of atherosclerotic disease, where more irregular wall changes with heterogeneous echogenicity is more common (Figure 1c). The distribution of areas with increased IMT $≥0.9$ mm for carotid and central arteries, and IMT $≥1.2$ mm in the aortic, is shown in Figure 2. 43% of the SLE cases had an IMT $≥1.2$ mm in the aortic arch compared to 20% of the healthy controls ($p = 0.006$). In SCA, CFA, and CCA, increased IMT ($≥0.9$ mm) was observed in 12% ($p = 0.002$), 15% ($p < 0.001$), and 3% (not significant), respectively in SLE, vs. 0%, 2%, and 0%, respectively among controls. All vessels with increased IMT showed a medium echogenicity without heterogeneous areas. There were no differences regarding vessel wall appearance between patients and controls.

Fibrotic stripes combined with medium echogenic homogenous wall thickening (of inflammatory appearance) (Figure 1d) were only seen in CFA; among 13/60 patients (8%) vs. 3/60 controls (2%) ($p = 0.007$).

Fifty percentage of the subjects with echogenic homogenous wall thickening and fibrotic stripes had no atherosclerotic plaques. Atherosclerotic plaques (Figure 1c) were found in 15/60 of SLE cases (25%) and in 2/60 controls (3%) ($p < 0.001$). Plaques were detected among 30% of patients with skin and joint involvement, 25% in LN and 20% in APS. As demonstrated in Figure 3, the plaques occurred at an earlier age among patients compared to controls. The mean age among SLE patients with plaques was $51.4 ± 8.1$ years compared to $60.0 ± 2.8$ years in controls. The occurrence of plaques was further associated to the duration of SLE ($p = 0.05$), whereas the association with disease activity using SLEDAI-2K was less apparent (illustrated in Figure 4). All plaques had homogeneous, medium-high echogenicity, which is typical for atherosclerosis. Sixty-seven percentage was located in the carotid bifurcation. Eight percentage of all plaques showed irregular cap. For the CCA and SCA the right side was dominant with plaques in 10 of the patients, and 5 patients had bilateral plaques. In the CFA, plaques were detected in two patients. Two of the healthy controls had bilateral plaques, both in the carotid bifurcation (Figure 2). No significant stenosis was detected, neither among SLE nor in control subjects. Only a few cases of missing data ($<0.1\%$) occurred at the US exams, due to poor visibility or technical problems.

**Relation of IMT to Traditional and SLE Depending Risk Factors**

Relation between traditional and disease dependent risk factors and IMT are shown in Table 3. Age was positively related to IMT in all vessels. When all factors in Table 1 (exclusion of diabetes, $n = 1$, and addition of APS and LN) were adjusted for age in a multivariate linear regression model no other factor influenced IMT in the aortic arch or SCA.

In the univariate analysis of CFA, SDI, antihypertensive treatment, β-blocking therapy, Angiotensin II receptor blocker (ARB)/Angiotensin-converting enzyme (ACE) inhibitor treatment, BMI, waist circumference, sagittal abdominal diameter, systolic and diastolic blood pressure, cholesterol, LDL, triglycerides, estimated glomerular filtration rate (GFR) and hsCRP were all related to IMT. However, when all significant variables were included in a multiple linear regression model, age ($B = 0.006$, $p = 0.009$), sagittal abdominal diameter ($B = 0.015$, $p = 0.016$), diastolic blood pressure ($B = 0.005$, $p = 0.026$) and cholesterol ($B = 0.052$, $p = 0.031$) remained as significant risk factors for IMT in CFA ($R^2 = 0.577$).

In multiple analysis of CFA, age ($B = 0.005$, $p < 0.001$), male sex (female $B = −0.079$, $p = 0.031$) and presence of Raynaud...
### TABLE 1 | Detailed characteristics of included patients and controls presented as mean±SD or n (%).

| Background variables | All SLE (n = 60) | Controls (n = 60) | LN (n = 20) | APS (n = 20) | Skin and joint (n = 20) |
|-----------------------|------------------|------------------|-------------|-------------|------------------------|
| Age at examination (years) | 43.2 ± 11.3 | 43.0 ± 11.4 | 41.6 ± 10.4 | 45.2 ± 12.2 | 42.9 ± 11.7 |
| Female gender, n (%) | 52 (87) | 52 (87) | 18 (90) | 15 (75) | 19 (95) |
| Duration of SLE (years) | 12.0 ± 9.4 | N/A | 10.7 ± 8.1 | 15.6 ± 12.2 | 9.6 ± 6.3 |
| SDI | 0.8 ± 1.1 | N/A | 0.8 ± 0.9 | 1.5 ± 1.4 | 0.4 ± 0.5 |
| SLEDAI-2K | 2.0 ± 2.1 | N/A | 1.6 ± 2.1 | 2.1 ± 2.4 | 2.2 ± 1.7 |
| Serologically active clinically quiescent SLE, n (%) | 29 (48) | N/A | 13 (65) | 10 (50) | 6 (30) |

#### Traditional risk factors and laboratory data

| Item | All SLE (n = 60) | Controls (n = 60) | LN (n = 20) | APS (n = 20) | Skin and joint (n = 20) |
|------|------------------|------------------|-------------|-------------|------------------------|
| Body mass index (BMI) (kg/m²) | 26.0 ± 4.2** | 24.0 ± 3.3 | 26.5 ± 3.4* | 25.6 ± 4.0 | 25.8 ± 5.1 |
| Waist circumference (cm) | 92.4 ± 12.1*** | 83.0 ± 10.0 | 93.2 ± 11.2** | 92.2 ± 12.8* | 91.8 ± 12.7 |
| Sagittal abdominal diameter (cm) | 20.6 ± 3.9** | 18.8 ± 2.7 | 20.7 ± 3.7 | 20.6 ± 3.9 | 20.6 ± 4.3 |
| Systolic blood pressure (mm Hg) | 115 ± 26 | 112 ± 18 | 117 ± 17 | 113 ± 32 | 118 ± 29 |
| Diastolic blood pressure (mm Hg) | 73 ± 11* | 68 ± 8 | 74 ± 12 | 73 ± 10 | 72 ± 9 |
| Diabetes mellitus, n (%) | 1 (2) | 0 | 0 | 1 (5) | 0 |
| Raynaud’s phenomenon, n (%) | 16 (27) | 9 (15) | 4 (20) | 5 (25) | 7 (35) |
| Estimated glomerular filtration rate (mL/min/1.73 m²) | 84 ± 16 | Not available | 85 ± 14 | 79 ± 18 | 87 ± 13 |
| Total cholesterol (mmol/L) | 4.7 ± 1.0 | 4.9 ± 1.1 | 4.5 ± 1.0 | 4.7 ± 0.8 | 4.9 ± 1.1 |
| High-density lipoprotein (HDL) (mmol/L) | 1.6 ± 0.5 | 1.7 ± 0.4 | 1.5 ± 0.4 | 1.6 ± 0.5 | 1.6 ± 0.4 |
| Low-density lipoprotein (LDL) (mmol/L) | 2.6 ± 0.8 | 2.6 ± 0.9 | 2.5 ± 0.9 | 2.5 ± 0.7 | 2.9 ± 0.9 |
| Triglycerides (TG) (mmol/L) | 1.1 ± 0.7 | 1.2 ± 0.6 | 1.2 ± 0.6 | 1.3 ± 1.0 | 0.9 ± 0.4 |
| High-sensitivity CRP (mg/L) | 2.2 ± 2.8 | 2.0 ± 3.7 | 1.4 ± 1.3 | 2.7 ± 3.4 | 2.5 ± 3.2 |
| Anti-dsDNA (IU/mL) | 88 ± 200 | N/A | 71 ± 115 | 89 ± 200 | 86 ± 202 |
| Complement protein 3 (g/L) | 1.0 ± 0.2 | N/A | 1.0 ± 0.2 | 0.9 ± 0.2 | 1.0 ± 0.2 |
| Complement protein 4 (g/L) | 0.2 ± 0.1 | N/A | 0.1 ± 0.1 | 0.2 ± 0.1 | 0.2 ± 0.1 |

#### Medical treatment, ongoing

| Item | All SLE (n = 60) | Controls (n = 60) | LN (n = 20) | APS (n = 20) | Skin and joint (n = 20) |
|------|------------------|------------------|-------------|-------------|------------------------|
| Antimalarial agents, n (%) | 54 (90) | 0 | 20 (100) | 16 (80) | 18 (90) |
| Anthypertensives, n (%) | 20 (33) | 0 | 11 (55) | 6 (30) | 3 (15) |
| Beta-blockers, n (%) | 5 (8) | 0 | 1 (5) | 1 (5) | 3 (15) |
| ARB/ACE inhibitors, n (%) | 15 (25) | 0 | 9 (45) | 4 (20) | 2 (10) |
| Other anthypertensives, n (%) | 4 (7) | 0 | 2 (10) | 1 (5) | 1 (5) |
| Steroidal corticosteroid therapy n (%) | 31 (52) | 0 | 12 (60) | 9 (45) | 10 (50) |
| Mean daily Prednisolone dose (mg) | 4.5 | 0 | 5.4 | 3.8 | 4.2 |
| Warfarin therapy, n (%) | 11 (18) | 0 | 1 (5) | 10 (50) | 0 |
| Antiplaquelet therapy, n (%) | 11 (18) | 0 | 5 (25) | 6 (30) | 0 |
| Statin therapy n (%) | 5 (8) | 0 | 2 (10) | 3 (15) | 0 |
| DMARD therapy, n (%) | 27 (45) | 0 | 11 (55) | 9 (45) | 7 (35) |
| Mycophenolate mofetil, n (%) | 16 (27) | 0 | 11 (55) | 4 (20) | 1 (5) |
| Methotrexate, n (%) | 5 (8) | 0 | 0 | 1 (5) | 4 (20) |
| Azathioprine, n (%) | 3 (5) | 0 | 0 | 2 (10) | 1 (5) |
| Sirolimus, n (%) | 2 (3) | 0 | 0 | 1 (5) | 1 (5) |
| Dehydroepiandrosterone, n (%) | 1 (2) | 0 | 1 (2) | 0 | 0 |
| Biologics, n (%) | 4 (7) | 0 | 3 (15) | 1 (5) | 0 |
| Bortezomib, n (%) | 1 (2) | 0 | 1 (5) | 0 | 0 |
| Rituximab, n (%) | 1 (2) | 0 | 1 (5) | 0 | 0 |
| Belimumab, n (%) | 2 (3) | 0 | 1 (5) | 1 (5) | 0 |

Subgroups compared to all controls. p < 0.05*, p < 0.01**, p < 0.001***.

ACE, angiotensin converting enzyme; APS, Antiphospholipid syndrome; ARB, angiotensin II receptor blocker; CRP, C-reactive protein; DMARDs, Disease Modifying Anti-Rheumatic Drugs; LN, lupus nephritis; N/A, not applicable; SDI, SLICC/ACR damage index; SLE, Systemic lupus erythematosus.
phenomenon ($B = 0.066, p = 0.026$) remained significant ($R^2 = 0.395$).

In the univariate analysis, duration of SLE significantly influenced IMT in ICA but not in CCA or CFA, where the $p$-values were just above the threshold of significance. However, all significances for disease duration were lost in the multivariate analyses. Smoking habits neither influenced IMT in the univariate nor in the multivariate analyses.

**Relation Between Plaques and Risk Factors**

As demonstrated in Table 4, atherosclerotic plaques were significantly and positively related to age, SLE duration, waist circumference, sagittal abdominal diameter, ever smoking, diastolic blood pressure, Raynaud phenomenon, total cholesterol, and triglycerides when patients with plaques were compared to those without.

**TABLE 2 | IMT in measured vessels.**

| Vessel         | All SLE ($n = 60$) | Controls ($n = 60$) | LN ($n = 20$) | APS ($n = 20$) | Skin and Joint ($n = 20$) |
|----------------|-------------------|---------------------|--------------|---------------|---------------------------|
| IMT (mm) mean ± SD | IMT (mm) mean ± SD | IMT (mm) mean ± SD | IMT (mm) mean ± SD | IMT (mm) mean ± SD |
| CCA            | 0.56 ± 0.10       | 0.54 ± 0.13         | 0.54 ± 0.07  | 0.58 ± 0.11   | 0.55 ± 0.10               |
| ICA            | 0.52 ± 0.17**     | 0.45 ± 0.09         | 0.56 ± 0.20**| 0.53 ± 0.13** | 0.47 ± 0.12               |
| SCA            | 0.58 ± 0.19*      | 0.53 ± 0.13         | 0.56 ± 0.08  | 0.61 ± 0.16   | 0.57 ± 0.13               |
| AxA            | 0.49 ± 0.10       | 0.48 ± 0.10         | 0.50 ± 0.15  | 0.52 ± 0.15   | 0.54 ± 0.21               |
| Aortic arch    | 1.21 ± 0.63**     | 0.98 ± 0.25         | 1.27 ± 1.05  | 1.26 ± 0.29***| 1.11 ± 0.24               |
| CFA            | 0.57 ± 0.23**     | 0.49 ± 0.11         | 0.56 ± 0.22  | 0.62 ± 0.21** | 0.57 ± 0.22               |
| SFA            | 0.44 ± 0.11       | 0.42 ± 0.10         | 0.44 ± 0.12  | 0.45 ± 0.10   | 0.44 ± 0.12               |

SLE, systemic lupus erythematosus; APS, antiphospholipid syndrome; IMT, intima media thickness; mm, millimeter; CCA, common carotid artery; ICA, internal carotid artery; SCA, subclavian artery; AxA, axillary artery; CFA, common femoral artery; SFA, superficial femoral artery.

Subgroups compared to all controls. *$p < 0.05$, **$p < 0.01$, ***$p < 0.001$. 

**FIGURE 2 | Number of SLE patients with each phenotypic subgroup and controls with areas showing increased IMT ($\geq 0.9$ mm for CCA, ICA, SCA, CFA; $\geq 1.2$ mm for the aortic arch). Plaques (gray areas) were distributed as follows: right/left carotid bifurcation: SLE, $n = 9/5$; controls 2/2, proximal SCA right SLE, $n = 2$, CFA right/left SLE, $n = 3/1$. APS, antiphospholipid syndrome; C, controls; CCA, common carotid artery; CFA, common femoral artery; ICA, internal carotid artery; IMT, intima-media thickness; LN, lupus nephritis; mm, millimeter; SCA, subclavian artery; SLE, systemic lupus erythematosus.**
When all significant variables were included in a multivariate logistic regression model, age ($B = 0.109$, $p = 0.017$), waist circumference ($B = 0.073$, $p = 0.040$) and smoking habits ($B = 2.657$, $p = 0.008$) remained significant for occurrence of plaques (Nagelkerke $R^2 = 0.555$).

**DISCUSSION**

In this study of well-characterized SLE patients, the great majority with clinically inactive disease, thicker IMT detected with US was observed in ICA, CFA, SCA, and the aortic arch compared to healthy controls, whereas IMT in CCA did not differ. By using this protocol, we were able to detect widespread vascular affection as measured with increased IMT, affected vessel wall appearance, and atherosclerotic plaques. The appearance of the vessel walls in patients with SLE has previously not been studied in detail.

A pathologic cutoff value of IMT $\geq 0.9$ mm was chosen for CCA, ICA, SCA, and CFA according to the latest ESH/ESC hypertension guidelines (29). However, the normal limits of IMT remain a controversial topic. According to the ESH/ESC hypertension guidelines, the relationship of IMT with CVD risk is continuous, and carotid IMT $>0.9$ mm has been reconfirmed as a marker of asymptomatic organ damage (29). For the aortic arch, a cutoff value of $\geq 1.2$ mm was chosen as IMT in the aortic arch usually is higher than in other vessels based on the findings reported by Bulut et al. albeit this cutoff was based on a group of patients with risk factors for coronary atherosclerosis (30). It is also necessary to keep in mind that IMT is an age-dependent value (31). Normal values in other vessel areas are not well-defined. Concerning CFA, Ayşe et al. studied vessels in patients with CVD risk factors and defined IMT of 1.1 mm as pathological. Furthermore, they showed that IMT in CFA correlated with IMT in CCA (32).

Previous studies used US in SLE for both risk assessment and follow-up (33), but several studies have focused mainly on IMT and the presence of plaques seen in CCA (3, 34, 35). Sporadic studies have evaluated the benefit of US in other vessels (36–38). Herein, we were not able to detect differences in IMT of CCA between patients and controls matched for age and sex, and only 3% of the SLE cases in our study displayed increased IMT $\geq 0.9$ mm in CCA. Other vessels than CCA could be at least as important to investigate.

Areas of increased IMT ($\geq 0.9$ mm in CCA, ICA, SCA, and CFA; $\geq 1.2$ mm in the aortic arc) without atherosclerotic plaques showed regular wall thickening of medium echogenicity. We have recently shown that an extended US protocol is of value for the assessment of giant cell arteritis (39) and Takayasu arteritis (28). In these diseases, US appearance of the vessel walls was characterized by a smooth, circumferential, homogenous increased IMT, with or without fibrotic stripes depending on different stages of the disease.

We did not find any differences with regard to vessel wall appearance between SLE patients and matched controls. The intima media among SLE cases was smooth and homogeneous with discrete increased thickness, and fibrotic stripes were usually not observed. This appearance can be seen in inflammatory diseases, with increasing age, as an early sign of atherosclerosis, or due to hypertrophy of the arterial wall (28, 31, 39). The vessel wall changes may thus be discrete but significant in SLE.
The hyperechogenic fibrotic stripes seen in CFA of some patients were similar to those seen in arteritis (28). In arteritis, it is unclear whether these stripes result from early atherosclerosis accompanying inflammation or if they are secondary to the vasculitic process (40). However, the parallel stripes and the smooth homogeneous appearance in vasculitis differ from more irregular findings in atherosclerosis.

The pathogenetic mechanisms of increased IMT in SLE are not clear. Age influenced IMT of all vessel areas. When adjusting for age, only a few traditional and SLE-related risk factors influenced IMT of SCA, AxA, the aortic arch, and SPA. However, in univariate analysis of CFA, IMT was influenced by age, SDI, antihypertensive therapy, β-blocking therapy, ARB/ACE inhibitor treatment, BMI, waist circumference, sagittal abdominal diameter, systolic and diastolic blood pressure, cholesterol, LDL, triglycerides, estimated GFR, and hsCRP. In the multivariate analysis, four factors remained significant as explaining factors for IMT in CFA: age, sagittal abdominal diameter, diastolic blood pressure, and cholesterol. In CCA, age, male sex, and presence of Raynaud remained as significant explaining factors, whereas smoking habits did not. None of the controls and 14/60 SLE cases (23%) had been tobacco smokers, and most of them had finished smoking.

In the univariate analysis only, duration of SLE influenced IMT of ICA but did not reach significance in CCA or CFA (Table 3). Low statistical power and the possibility that disease duration is neutralized by the patients' age are reasonable explanations to why SLE duration did not remain significant in the multivariate analysis. Previous studies indicate that higher age at SLE onset, SLE duration (6, 41), long-time use

### TABLE 3 | IMT related to background variables, traditional risk factors, laboratory tests A and medical treatment in an univariate regression model for internal carotid artery (ICA), common carotid artery (CCA) and common femoral artery (CFA) among all 60 patients with SLE.

| Background variables | All SLE (n = 60) ICA | All SLE (n = 60) CCA | All SLE (n = 60) CFA |
|----------------------|----------------------|----------------------|----------------------|
| Age at examination (years) | 0.005 0.003 | 0.006 0.001 | 0.012 0.001 |
| Female gender | −0.045 0.058 | −0.085 0.058 | 0.074 NS |
| Duration of SLE (years) | 0.005 0.116 | 0.003 0.053 | 0.007 0.051 |
| SDI | 0.029 NS | 0.020 NS | 0.065 0.019 |
| Traditional risk factors and laboratory data | | | |
| Body mass index (BMI) (kg/m^2) | 0.001 NS | 0.002 NS | 0.022 0.002 |
| Waist circumference (cm) | 0.002 NS | 0.002 NS | 0.010 <0.001 |
| Sagittal abdominal diameter (cm) | 0.007 NS | 0.003 NS | 0.032 <0.001 |
| Ever smoker (former or current) | 0.087 0.066 | 0.012 NS | 0.035 NS |
| Systolic blood pressure (mm Hg) | 0.519 NS | 0.001 NS | 0.002 0.035 |
| Diastolic blood pressure (mm Hg) | 0.002 NS | 0.002 NS | 0.012 <0.001 |
| Raynaud's phenomenon | 0.104 0.020 | 0.095 0.006 | 0.063 NS |
| Estimated glomerular filtration rate (mL/min/1.73 m^2) | −0.03 0.026 | 0.002 0.082 | 0.012 <0.001 |
| Total cholesterol (mmol/L) | 0.036 0.084 | 0.043 0.005 | 0.116 <0.001 |
| High-density lipoprotein (HDL) (mmol/L) | 0.019 NS | 0.541 NS | 0.113 0.078 |
| Low-density lipoprotein (LDL) (mmol/L) | 0.028 NS | 0.038 0.039 | 0.087 0.016 |
| Triglycerides (TG) (mmol/L) | 0.045 NS | 0.057 0.006 | 0.106 0.008 |
| High-sensitivity CRP (mg/L) | −0.003 0.026 | −0.004 0.476 | 0.022 0.031 |
| Medical treatment, ongoing | | | |
| Antimalarial agents | −0.105 NS | −0.043 NS | −0.126 NS |
| Antihypertensives | −0.026 NS | 0.003 NS | 0.155 0.018 |
| Beta-blockers | 0.106 NS | 0.079 NS | 0.321 0.005 |
| ARB/ACE inhibitors | 0.016 NS | 0.007 NS | 0.170 0.012 |
| Other antihypertensives | −0.083 NS | −0.049 NS | −0.076 NS |
| Glucocorticoid therapy | −0.018 NS | −0.012 NS | 0.092 NS |
| Mean daily Prednisolone dose (mg) | −0.007 NS | −0.004 NS | 0.014 NS |
| Warfarin therapy | 0.003 NS | 0.018 NS | 0.042 NS |
| Antiplatelet therapy | −0.010 NS | 0.027 NS | 0.047 NS |
| Statin therapy | 0.093 NS | 0.063 NS | 0.213 0.065 |
| DMARD therapy | 0.023 NS | 0.001 NS | −0.019 NS |

ACE, angiotensin converting enzyme; APS, antiphospholipid syndrome; ARB, angiotensin II receptor- blocker; B, Beta coefficient; CRP, C-reactive protein; DMARD, Disease Modifying Anti-Rheumatic Drugs; SDI, SLICC/ACR damage index.
of corticosteroids, hypercholesterolemia, and postmenopausal status are important with regard to increased CVD risk (6). Long-time use of steroids has been associated with premature atherosclerosis (42). Herein, 52% of patients were prescribed a daily dose of glucocorticoids, but we could not detect any influence on IMT. We were not able to estimate accumulated life-time intake of glucocorticoids, but most patients were in quiescent phase of their disease on a stable dose of steroids during the last 6 months. Ajeganova et al. observed progression of IMT in CCA among patients with SLE during a 7-year surveillance and showed that traditional risk factors, LN, and higher doses of corticosteroids were associated with the progression of IMT (33). By comparing the phenotypic subgroups and controls, we found that IMT of ICA, CFA, and the aortic arch was higher in the APS group. In the LN group, only IMT in ICA was higher compared to controls. However, no significant differences were found between the subgroups.

Concerning occurrence of plaques, similar risk factors were observed as for increased IMT in CFA. Thus, pathogenic mechanisms promoting atherosclerosis seems more likely to contribute to increased IMT than inflammation per se. Nevertheless, atherosclerosis and inflammation appear to be closely interrelated (12, 13). Furthermore, several risk factors may influence IMT differently in different arterial areas with varying immunological properties, i.e., divergent Toll-like receptors of dendritic cells are normally distributed in the vessel walls (43).

Measuring IMT with US has low interobserver and intraobserver variability (28, 44), and it has been increasingly used as an indicator of atherosclerosis in clinical and epidemiological research (45). It has been recommended for use as cardiovascular risk assessment by the American College of Cardiology/American Heart association Task force on Practice Guidelines (46). With high-frequency US, it is possible to detect and measure differences of 0.1 mm. In our study, the magnitude of increased IMT in SLE compared to controls was 0.05–0.23 mm in different vessels (Table 2). Differences of IMT in inflammatory diseases, i.e., Takayasu arteritis and giant cell arteritis, may vary several millimeters over time and due to medication. Vessel wall changes in inflammatory disease can be evaluated by different imaging modalities, such as computerized tomography scan, arterial angiography, magnetic resonance imaging (MRI), positron emission tomography (PET), and combined PET-MRI (47). Compared to US, however, these methods have lower resolution, are more expensive, and expose the patient for radiation and have an overall lower availability. For future studies, echocardiography as a complement to the examinations performed in the present study could be considered to achieve an even more complete picture.

The cross-sectional design and the rather low number of examined individuals constitute limitations of the present study. Although the SLE patients were well-matched to the healthy control group, slightly higher measurements regarding waist circumference, sagittal abdominal diameter, and BMI were recorded among the SLE cases. The assessment of the vessel walls and the grading of echogenicity are per definition subjective. Interobserver variability was not possible to study in this investigation as the same sonographer did all online and offline measurements. In contrast, the well-characterized population and the patients’ universal access to health care constitute strengths of the present study.

CONCLUSION

Among SLE patients without presence of plaques, high-frequency US of multiple arterial areas revealed increased wall thickness with predominantly medium echogenic appearance highlighting possible inflammation or early atherosclerosis. Our findings in CFA emphasize the importance of examining several areas of the arterial tree, which could have implications for clinical practice.
Increased number of plaques was observed in SLE compared to age- and sex-matched healthy controls. We found similar risk factors for increased IMT and occurrence of plaques, possibly indicating atherosclerotic mechanisms rather than inflammation, but atherosclerosis and inflammation appear to be closely interrelated. These data call for confirmation, and careful follow-up is needed before firm conclusions regarding cardiovascular management can be drawn.

**DATA AVAILABILITY STATEMENT**

All datasets generated for this study are included in the article/Supplementary Material.

**ETHICS STATEMENT**

The studies involving human participants were reviewed and approved by The Regional Ethics board in Linköping. The patients/participants provided their written informed consent to participate in this study.

**AUTHOR CONTRIBUTIONS**

CSV: study design, methodology, investigation, formal analysis, and manuscript writing. PE and CSj: study design, investigation, formal analysis, manuscript writing, and supervision. HZ: study design, methodology, investigation, formal analysis, manuscript writing, and supervision. All authors contributed to the article and approved the submitted version.

**FUNDING**

This study was supported by Region Östergötland (ALF grants), the Swedish Rheumatism Association, the King Gustaf V’s 80-year Anniversary foundation, the King Gustaf V and Queen Victoria’s Freemasons foundation, and Linköping University hospital Research Fund.

**ACKNOWLEDGMENTS**

We acknowledge Marianne Pettersson for logistic help when planning and performing the study, for blood sampling and for taking care of the patients and controls at their visits to the Rheumatology unit. Senior Professor of Rheumatology Thomas Skogh and Nora Østrup are both acknowledged for kindly reviewing the manuscript.

**SUPPLEMENTARY MATERIAL**

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fmed.2020.581336/full#supplementary-material

**REFERENCES**

1. Kaul A, Gordon C, Crow MK, Toura Z, Urowitz MB, van Vollenhoven R, et al. Systemic lupus erythematosus. Nat Rev Dis Primers. (2016) 2:16039. doi: 10.1038/nrdp.2016.39
2. Bernatsky S, Boivin JF, Joseph L, Manzi S, Ginzer E, Gladman DD, et al. Mortality in systemic lupus erythematosus. Arthritis Rheum. (2006) 54:2550-7. doi: 10.1002/art.21955
3. Gustafsson JT, Herlitz Lindberg M, Gunnarsson I, Pettersson S, Elvin K, Öhrvik J, et al. Excess atherosclerosis in systemic lupus erythematosus. A matter of renal involvement: case control study of 281 SLE patients and 281 individually matched population controls. PLoS ONE. (2017) 12:e0174572. doi: 10.1371/journal.pone.0174572
4. Esdaile JM, Abrahamowicz M, Grodzicky T, Li Y, Panaritis C, du Berger R, et al. Increased number of plaques was observed in SLE compared to age- and sex-matched healthy controls. We found similar risk factors for increased IMT and occurrence of plaques, possibly indicating atherosclerotic mechanisms rather than inflammation, but atherosclerosis and inflammation appear to be closely interrelated. These data call for confirmation, and careful follow-up is needed before firm conclusions regarding cardiovascular management can be drawn.

**AUTHOR CONTRIBUTIONS**

CSV: study design, methodology, investigation, formal analysis, and manuscript writing. PE and CSj: study design, investigation, formal analysis, manuscript writing, and supervision. HZ: study design, methodology, investigation, formal analysis, manuscript writing, and supervision. All authors contributed to the article and approved the submitted version.

**FUNDING**

This study was supported by Region Östergötland (ALF grants), the Swedish Rheumatism Association, the King Gustaf V’s 80-year Anniversary foundation, the King Gustaf V and Queen Victoria’s Freemasons foundation, and Linköping University hospital Research Fund.

**ACKNOWLEDGMENTS**

We acknowledge Marianne Pettersson for logistic help when planning and performing the study, for blood sampling and for taking care of the patients and controls at their visits to the Rheumatology unit. Senior Professor of Rheumatology Thomas Skogh and Nora Østrup are both acknowledged for kindly reviewing the manuscript.

**SUPPLEMENTARY MATERIAL**

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fmed.2020.581336/full#supplementary-material

**REFERENCES**

1. Kaul A, Gordon C, Crow MK, Toura Z, Urowitz MB, van Vollenhoven R, et al. Systemic lupus erythematosus. Nat Rev Dis Primers. (2016) 2:16039. doi: 10.1038/nrdp.2016.39
2. Bernatsky S, Boivin JF, Joseph L, Manzi S, Ginzer E, Gladman DD, et al. Mortality in systemic lupus erythematosus. Arthritis Rheum. (2006) 54:2550-7. doi: 10.1002/art.21955
3. Gustafsson JT, Herlitz Lindberg M, Gunnarsson I, Pettersson S, Elvin K, Öhrvik J, et al. Excess atherosclerosis in systemic lupus erythematosus. A matter of renal involvement: case control study of 281 SLE patients and 281 individually matched population controls. PLoS ONE. (2017) 12:e0174572. doi: 10.1371/journal.pone.0174572
4. Esdaile JM, Abrahamowicz M, Grodzicky T, Li Y, Panaritis C, du Berger R, et al. Traditional Framingham risk factors fail to fully account for accelerated atherosclerosis in systemic lupus erythematosus. Arthritis Rheum. (2001) 44:2331-7. doi: 10.1002/1529-0131(200110)44:10<2331:: aid-art395>3.0.co;2-i
5. Hak AE, Karlsson EW, Feskanich D, Stampfer MJ, Costenbader KH. Systemic lupus erythematosus and the risk of cardiovascular disease: results from the nurses health study. Arthritis Rheum. (2009) 61:1596–402. doi: 10.1002/art.24537
6. Manzi S, Mellahn EN, Rairie JE, Conte CG, Medsger TA Jr., Jansen-McWilliams L, et al. Age-specific incidence rates of myocardial infarction and angina in women with systemic lupus erythematosus: comparison with the Framingham study. Am J Epidemiol. (1997) 145:408–15. doi: 10.1093/oxfordjournals.aje.a009122
7. Arkema E, Svenningsson E, Von Euler M, Sjowall C, Simard JF. Stroke in systemic lupus erythematosus: a Swedish population-based cohort study. Ann Rheum Dis. (2017) 76:1544-49. doi: 10.1136/annrheumdis-2016-210973
8. Miyakos S, Lockshin MD, Atsumi T, Branch DW, Brey RL, Cervera R, et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost. (2006) 4:295–306. doi: 10.1111/j.1538-7836.2006.01753.x
9. Ünlü O, Stephane Zuly S, Erkan D. The clinical significance of antiphospholipid antibodies in systemic lupus erythematosus. Eur J Rheumatol. (2016) 3:75–84. doi: 10.5132/eurjrh.2015.0085
10. Frodlund M, Vikerfors A, Grosso B, Skogh T, Wettert J, Elvin K, et al. Immunoglobulin A anti-phospholipid antibodies in Swedish cases of systemic lupus erythematosus: associations with disease phenotypes, vascular events and damage accrual. Clin Exp Immunol. (2018) 194:27–38. doi: 10.1111/cei.13180
11. Pignoli P, Tremoli E, Poli A, Oreste P, Paololetti R. Intimal plus medial thickness of the arterial wall: a direct measurement with ultrasound imaging. Circulation. (1986) 74:1399–406. doi: 10.1161/01.CIR.74.6.1399
12. Frostegård J. Immunity, atherosclerosis and cardiovascular disease. BMC Med. (2013) 11:117. doi: 10.1186/1741-7015-11-117
13. Geovanini GR, Libby P. Atherosclerosis and inflammation: overview and updates. Clin Sci. (2018) 132:1243–52. doi: 10.1042/CS20180306
14. Liu KH, Chu WC, Kong AP, Choi Ko GT, Ma RC, Chan JW, et al. US assessment of medial arterial calcification: a sensitive marker of diabetes-related microvascular and macrovascular complications. Radiology. (2012) 265:294–302. doi: 10.1148/radiol.12112440
15. Park TH. Evaluation of carotid plaque using ultrasound imaging. J Cardiovasc Ultrason. (2016) 24:91-5. doi: 10.4250/jcu.2016.24.2.91
16. Sun Y, Yip PK, Jeng JS, Hwang BS, Lin WH. Ultrasonographic study and long-term follow-up of Takayasu’s arteritis. Stroke. (1996) 27: 2178–82. doi: 10.1161/01.STR.27.12.2178
17. Schmidt WA, Gronmica-Ihle E. What is the best approach to diagnosing large-vessel vasculitis? Best Pract Res Clin Rheumatol. (2005) 19:223–42. doi: 10.1016/j.berh.2005.01.006
18. Schmidt WA. Role of ultrasound in the understanding and management of vasculitis. Ther Adv Musculoskelet Dis. (2014) 6:39–47. doi: 10.1177/1759720X13512256
19. Stein J, Korczar C, Hurst R, Lonn E, Kendall C, Mohler ER, et al. Use of carotid ultrasound to identify subclinical vascular disease and evaluate cardiovascular disease risk: a consensus statement from the American Society of Echocardiography Carotid Intima-Media Thickness Task Force. Endorsed by the Society for Vascular Medicine. J Am Soc Echocardiogr. (2008) 21:93–190. doi: 10.1016/j.echo.2007.11.011
20. Tan EM, Cohen AS, Fries JF, Masi AT, McClure DJ, Rothfield NF, et al. The 1987 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum. (1988) 32:1238–49. doi: 10.1002/art.1780320112
21. Petri M, Orban AM, Alarcon GS, Gordon C, Merrill JT, Fortin PR, et al. Derivation and validation of the Systemic Lupus International Collaborating Clinics classification criteria for systemic lupus erythematosus. Arthritis Rheum. (2012) 64:2767–86. doi: 10.1002/art.34473
22. Dahlof B, Wedel H, Westerlind L, Dahlof C, Ryden L, for the STOP-Hypertension trial participants. The Scandinavian Trial in Preventing Heart Disease by Reducing Blood Pressure in Essential Hypertension. Eur Heart J. (2003) 24:1295–303. doi: 10.1016/S0195-668X(03)00322-6
23. Sjöwall E, Svensson H, Eriksson P, Zachrisson H. Vascular ultrasound for monitoring of inflammatory activity in Takayasu Arteritis. Clin Physiol Funct Imaging. (2020) 40:37–45. doi: 10.1111/cpf.12601
24. Kravvariti E, Konstantonis G, Tentolouris N, Sfikakis P, Tsekouras K, The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. Copyright © 2020 Svensson, Eriksson, Zachrisson and Sjöwall. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.